PTC Therapeutics beats Q2 estimates with earnings of $0.92 per share

Zacks Investment Research··Read original
3▲1 ▼0Impact / 5
Summary · why it matters

PTC Therapeutics reported second-quarter earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share by a surprise of 641.18%. Revenue came in at $360.52 million, surpassing the consensus estimate by 22.24% and up from $178.88 million a year ago. The company has topped consensus EPS estimates three times over the last four quarters. Shares have lost about 1.9% year to date, underperforming the S&P 500's gain of 6.9%. The current Zacks Rank for the stock is #3 (Hold).

Impact on assets 2

Biotech & Genomic Medicine▲